Loading quotes...

Forecast

The analysts' average price target is €6.35 (+229.02%). The median is €6.35 (+229.02%).

Buy	8
Hold	1
Sell	0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

AC Immune receives FDA fast-track designation for Parkinson vaccine Aci-7104

AC Immune has received FDA Fast Track designation for its drug candidate Aci-7104 for the treatment of Parkinson’s disease. The designation is intended to speed development and approval; Aci-7104 is in a phase 2 study (Vacsyn) and showed safety, tolerability and an immune response in all participants. The vaccine targets misfolded alpha-synuclein proteins in the brain and is intended for use in early stages of the disease. » More on finanzen.net
AC Immune reports positive interim data for Alzheimer’s drug ACI-24

AC Immune reports 12‑month interim data from the first three cohorts of the Phase‑1b/2 ABATE study in prodromal Alzheimer’s disease. ACI‑24 was generally safe and well tolerated at the doses tested; no ARIA‑E cases occurred, and anti‑Abeta antibody responses showed a dose‑response relationship. A fourth cohort (AD4) with an additional adjuvant was initiated to boost immunogenicity. AC Immune holds an option and license agreement with Takeda and has already received upfront and milestone payments; further payments and royalties are possible. » More on de.investing.com
AC Immune receives $4 million to extend Parkinson phase 2 study

AC Immune has received a $4 million research grant from the Vijay and Marie Goradia Charitable Foundation to fund a two‑year extension of part 1 of the phase 2 VacSYn study with ACI-7104 for early‑stage Parkinson’s. The funds are intended to finance long‑term safety and efficacy data; final data from part 1 are expected in the second half of 2026. The company has a market capitalization of $210 million, its stock is down about 32% year‑to‑date and trades at $2.12. » More on de.investing.com
AC Immune: TDP‑43 PET tracer ACI‑19626 shows increased brain uptake in ALS patients

Phase‑1 data show that the PET tracer ACI‑19626 has increased uptake in ALS patients compared with healthy controls, particularly in the brainstem and precentral gyrus. The tracer demonstrated good safety, acceptable dosimetry, and rapid brain uptake and clearance. The Phase‑1 study has been expanded (part 2) and can include up to 30 patients with FTD, ALS, or LATE. AC Immune is valued at around USD 281 million; analysts see price targets of USD 7–12 per share. » More on de.investing.com
AC Immune: CEO Andrea Pfeifer steps down after 23 years

AC Immune announced that co-founder and CEO Dr Andrea Pfeifer will step down at the upcoming general meeting after 23 years to spend more time with her family. Board chairman Dr Martin Züfel will serve as interim CEO while a leading industry advisor leads the search for a permanent successor. Pfeifer will move into an advisory role, become honorary chair of the board and co-chair of the scientific advisory board. The company develops precision therapeutics for Alzheimer’s and Parkinson’s and has three candidates in clinical trials, as well as partnerships with Eli Lilly, Takeda and Johnson & Johnson. » More on de.investing.com

Financials

In the last quarter, AC Immune had revenue of €3.43m and net profit of -€9.24m

(EUR)	September 2026	YoY
Revenue	3.43m	241.10%
Gross profit	3.43m	241.10%
Net profit	-9.24m	45.52%
EBITDA	-9.18m	43.71%

Fundamentals

Metric	Value
Market capitalization	€197.57m
Number of shares	101.77m
52-week high/low	€3.54 - €1.83
Dividends	No
Beta	1.61
P/E ratio	-4.46
PEG ratio	-0.08
P/B ratio	6.60
P/S ratio	9.18

Company profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.